Annual report pursuant to Section 13 and 15(d)

INCOME TAXES

v3.7.0.1
INCOME TAXES
12 Months Ended
Dec. 31, 2016
INCOME TAXES  
INCOME TAXES

10. INCOME TAXES

For the years ended December 31, 2016, 2015 and 2014, our loss before income taxes was from domestic operations. For the years ended December 31, 2016, 2015 and 2014, we did not record a provision for income taxes due to our net loss.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets are as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

    

2016

    

2015

 

Deferred tax assets

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

297,445

 

$

276,740

 

Orphan drug and research and development credits

 

 

44,348

 

 

36,387

 

Deferred compensation

 

 

21,618

 

 

22,647

 

Capitalized research and development expenses

 

 

1,877

 

 

1,761

 

Other, net

 

 

3,069

 

 

4,966

 

Total deferred tax assets

 

 

368,357

 

 

342,501

 

Valuation allowance

 

 

(368,357)

 

 

(342,501)

 

Net deferred tax assets

 

$

 —

 

$

 —

 

 

The reconciliation of the statutory federal income tax rate to the effective tax rate was as follows:

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31,

 

 

    

2016

    

2015

    

2014

 

Federal statutory tax rate

 

(34.0)

%  

(34.0)

%  

(34.0)

%

Valuation allowance

 

35.0

%  

31.3

%  

32.3

%

Other, net

 

(1.0)

%  

2.7

%  

1.7

%  

Effective tax rate

 

0.0

%  

0.0

%  

0.0

%  

 

In general, under Section 382 of the Internal Revenue Code (Section 382), a corporation that undergoes an ownership change is subject to limitations on its ability to utilize its pre‑change net operating loss carryovers and tax credits to offset future taxable income. Our existing net operating loss carryforwards and tax credits are subject to limitations arising from ownership changes which occurred in previous periods. We finalized our analysis of potential ownership changes and concluded our Section 382 owner shift analysis during the year ended December 31, 2012. We have updated our net operating loss carryforwards to reflect the results of the Section 382 owner shift analysis as of December 31, 2016. We did not experience any significant changes in ownership in 2016 and 2015. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 and result in additional limitations.

As of December 31, 2016, we had net operating loss carryforwards for federal income tax purposes of approximately $826.7 million, which expire beginning in the year 2019 and state net operating loss carryforwards of approximately $303.7 million, which expire beginning in the year 2017. We had previously elected the three-factor apportionment formula pursuant to the Multistate Tax Compact, or MTC in determining the state net operating loss carryforwards for 2013 and 2014.  In October 2016, the U.S. Supreme Court denied a petition to review the California Supreme Court’s decision which disallowed taxpayers from electing using the three-factor apportionment formula.  Accordingly, we reduced our deferred tax assets and offsetting valuation allowance related to the California NOL calculated in 2013 and 2014 to reflect the single-sales formula. 

We have general business credits of approximately $33.0 million, which will expire beginning in 2023, if not utilized, and is comprised of research and development credits and orphan drug credits. We also have state research and development tax credits of approximately$25.7 million, which have no expiration date.

Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $25.9 million and decreased by approximately $14.2 million for the years ended December 31, 2016 and 2015, respectively.

Included in the valuation allowance balance at December 31, 2016 and 2015 is approximately $2.5 million of tax deductions related to the exercise of stock options prior to the adoption of ASC 718 which have not reflected as an expense for financial reporting purposes. Accordingly, any future reduction in the valuation allowance relating to this amount will be credited directly to equity and not reflected as an income tax benefit in the statement of operations. As a result of certain realization requirements, the table of deferred tax assets and liabilities shown above does not include loss carryforward tax assets of approximately $1.7 million at December 31, 2016 and 2015 that arose directly from (or the use of which was postponed by) tax deductions related to stock‑based compensation expense in excess of compensation expense recognized for financial reporting. Equity will be increased by approximately $1.7 million if and when such deferred tax assets are ultimately realized.

The following table summarizes the activity related to our gross unrecognized tax benefits (in thousands):

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31,

 

 

    

2016

    

2015

 

Balance at the beginning of the year

 

$

17,278

 

$

5,374

 

Increase (decrease) related to prior year tax positions

 

 

(11,332)

 

 

11,332

 

Increase related to current year tax positions

 

 

957

 

 

572

 

Balance at the end of the year

 

$

6,903

 

$

17,278

 

 

Included in the balance of unrecognized tax benefits at December 31, 2016 and 2015, respectively, are $5.4 million and $12.2 million of tax benefits that, if recognized, would result in adjustments to other tax accounts, primarily deferred taxes. No income tax benefit would be realized due to the Company’s valuation allowance position. We do not anticipate a significant change to the unrecognized tax benefits over the next twelve months.

We are subject to taxation in the United States and in California. Because of net operating loss and research credit carryovers, substantially all of our tax years remain open to examination.

Our policy is that we recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We currently have no tax positions that would be subject to interest or penalties.